Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Concerned about drug–drug interactions between DOACs and prostate cancer therapies?
New study of 2297 patients from Ontario and Alberta:
- No elevated risk for thrombosis with DOACs plus enzalutamide/ apalutamide
- No elevated risk for bleeding with DOAC plus abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, Manish M. Sood
Read the Full Article on Cancer
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 19, 2026, 01:53Thomas Dayspring: Understanding Genome and Lipid Interactions in Lipidology
-
Sep 19, 2026, 01:47Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
-
Sep 19, 2026, 01:44Patrick James Lynch: Mother of a Thousand Sons Premieres at BDC 2026
-
Sep 19, 2026, 01:41Genetic Fate Mapping Reveals Endothelial Cells During Venous Thrombus Resolution – RPTH Journal
-
Sep 19, 2026, 01:39Mostafa Hammam: Three Different Platelet Defects – One Common Symptom
-
Sep 19, 2026, 01:38Jeff Sternlicht: A Heart Attack Should Not Be the Starting Line
-
Sep 19, 2026, 01:28Luis Oliverio Ambriz Garcia: Key Points From the ASH 2026 Guidelines on Iron Deficiency
-
Sep 19, 2026, 01:27Farjah Algahtani: A New Era in the Treatment of Transfusion-Dependent Thalassaemia
-
Sep 19, 2026, 01:24Aravind Palraj: 2025 EULAR Behçet’s Syndrome Update – 5 Practical Take-Home Points